Abstract
The utility of longitudinal AST-To-platelet ratio index (APRI), a surrogate for hepatic fibrosis, is unknown.We compared APRI up to 9 years before liver-related death among 57 cases of viral hepatitis-infected men (91% HIVR) to matched controls. APRI was stable among controls but, among cases, increased 4.6%/year from 9 to 3 years predeath (PU0.10) and 30%/year during the 3 years predeath (P0.001). Thus, rapid APRI increase may predict impending liver-related death in HIV-viral hepatitis coinfection.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2636-2638 |
| Number of pages | 3 |
| Journal | AIDS |
| Volume | 32 |
| Issue number | 17 |
| DOIs | |
| State | Published - 2018 |
Funding
Funding/support: This work was funded by the National Center for Research Resources (NCRR) (1KL2RR025006-01 to J.C.P.) and the National Institute on Drug Abuse (NIDA) (5R03DA026094-02 to C.L.T.). Data in this manuscript were collected by the Multicenter AIDS Cohort Study (MACS). MACS (Principal Investigators): Johns Hopkins University Bloomberg School of Public Health (Joseph Margolick), U01-AI35042; Northwestern University (Steven Wolinsky), U01-AI35039; University of California, Los Angeles (Roger Detels), U01-AI35040; University of Pittsburgh (Charles Rinaldo), U01-AI35041; the Center for Analysis and Management of MACS, Johns Hopkins University Bloomberg School of Public Health (Lisa Jacobson), UM1-AI35043. The MACS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional co-funding from the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH). Targeted supplemental funding for specific projects was also provided by the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Deafness and Communication Disorders (NIDCD). MACS data collection is also supported by UL1-TR001079 (JHU ICTR) from the National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research and the Los Angeles Biomedical Research Institute at Harbor-UCLA CTSI, UL1TR000124. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH), Johns Hopkins ICTR, or NCATS. J.C.P. discloses grant support from Gilead Sciences and Merck and ownership interest in Bristol-Myers Squibb, Johnson and Johnson, Merck, and Abbvie. C.L.T. discloses grant support paid to her university from Gilead Sciences. All other authors have nothing to disclose.
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Infectious Diseases
